| abstract |
The invention relates to mutant pro-NRF and their use, in particular the use of mutant pro-NRF to obtain human beta-NRF. The invention discloses a method for producing biologically active human beta-NRF from an inactive, insoluble mutant pro-NRF. The mutant pro-NRF is substituted by any amino acid except Arg or Lys of the native RSKR region, at least in the R and K positions corresponding to positions 101 and 103 of the human pro-NRF sequence. |